FDA doubts efficacy of uniQure's Huntington's disease treatment

seekingalpha.com

FDA doubts uniQure's AMT-130 Huntington's disease treatment efficacy based on 12-month data. The company's Type A meeting with the FDA yielded no progress, potentially requiring an ethically questionable Phase III trial. uniQure is pursuing European and UK approval and exploring external control trials while facing pressure for its stock's upside.


With a significance score of 1.6, this news ranks in the top 33% of today's 27892 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


FDA doubts efficacy of uniQure's Huntington's disease treatment | News Minimalist